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Abstract
Background: H-1 parvovirus (H-1 PV), a rodent autonomous oncolytic parvovirus, has emerged as a novel class of promising
anticancer agents, because of its ability to selectively find and destroy malignant cells. However, to probe H-1 PV
multimodal antitumor potential one of the major prerequisites is to decipher H-1 PV direct interplay with human immune
system, and so prevent any risk of impairment.
Methodology/Principal findings: Non activated peripheral blood mononuclear cells (PBMCs) are not sensitive to H-1 PV
cytotoxic effect. However, the virus impairs both activated PBMC proliferation ability and viability. This effect is related to H-
1 PV infection as evidenced by Western blotting detection of H-1 PV main protein NS1. However, TCID50 experiments did
not allow newly generated virions to be detected. Moreover, flow cytometry has shown that H-1 PV preferentially targets B
lymphocytes. Despite seeming harmful at first sight, H-1 PV seems to affect very few NK cells and CD8+ T lymphocytes and,
above all, clearly does not affect human neutrophils and one of the major CD4+ T lymphocyte subpopulation. Very
interestingly, flow cytometry analysis and ELISA assays proved that it even activates human CD4+ T cells by increasing
activation marker expression (CD69 and CD30) and both effective Th1 and Th2 cytokine secretion (IL-2, IFN-c and IL-4). In
addition, H-1 PV action does not come with any sign of immunosuppressive side effect. Finally, we have shown the
efficiency of H-1 PV on xenotransplanted human nasopharyngeal carcinoma, in a SCID mouse model reconstituted with
human PBMC.
Conclusions/Significance: Our results show for the first time that a wild-type oncolytic virus impairs some immune cell
subpopulations while directly activating a Helper CD4+ T cell response. Thus, our data open numerous gripping
perspectives of investigation and strongly argue for the use of H-1 PV as an anticancer treatment.
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Introduction
Novel anticancer strategies aim at enhancing both tumor cell
death and antitumor immune response through recognition of
tumor antigens by the immune system [1,2]. As new approaches
for tumor targeting, replication-competent oncolytic viruses have
been drawing special attention for a while because they exert
specific antitumor effects in vivo [1,3,4,5,6].
More particularly, some autonomous parvoviruses, especially
H-1 parvovirus (H-1 PV), are able to replicate in and kill both
cancer cell lines and human primary cells cultured from patient
tumor samples [7] while remaining harmless for normal cells.
This remarkable feature, known as oncolysis, ultimately results in
the decrease of spontaneous, chemically induced and xenografted
tumor incidence in laboratory animals [2]. However, H-1 PV
oncosuppression seems to involve more than just tumor cell
killing. Indeed, H-1 PV may also exert a vaccination effect by
enhancing effective immune response as several studies tend to
suggest. For example, H-1 PV-mediated cell lysates stimulate
antigen presentation by dendritic cells, leading to cytotoxic T
lymphocyte activation and proinflammatory cytokine release [8].
Besides, H-1 PV in vivo antitumor effect has been reported to be
related to both direct oncolysis and immune response triggering
in a human hepatoma metastatic model [9]. More recently,
immunocompetent rats carrying syngenic gliomas were shown to
be more susceptible to H-1 PV oncosuppressive action than
immunodeficient ones xenografted with human glioma cells. The
former exhibited complete and stable cancer remission whereas
the latter were only partially cured, confirming the existence of a
major immunological component in H-1 PV therapeutic effect
[10]. But none of these studies investigated the direct interplay
between H-1 PV and immune system, particularly human
immune cells.
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32197With a view to using H-1 PV as an anticancer treatment, we
propose to decipher H-1 PV effect on human immune cells to
probe its multimodal antitumor potential as well as its harmless-
ness. As a first approach, we analyzed the effect of H-1 PV direct
inoculation on peripheral blood mononuclear cells (PBMCs) under
activation conditions or not. H-1 PV does not cause any major
changes in non activated PBMCs. On the contrary, activated ones
suffer both proliferation ability and viability impairment as well as
significant lysis, while sustaining overactivation and both Th1 and
Th2 type cytokine secretion. Very interestingly, further investiga-
tion indicated that H-1 PV does not only preserve CD4+ T cell
subpopulation but also enhances its activation status as well as
both IL-2 and IFN-c secretion. Any effective immune response
activation upon infection might get offset by the induction of a
regulatory response which would result in effector T cell
inhibition. So, CD4+CD25+ regulatory T cells were further
analyzed because they are able to inhibit antitumor immune
response and thus, are associated with the progression of cancer
[11,12]. These cells show neither viability nor proliferation or
phenotypical alteration. Surprisingly, their suppressive activity is
even inhibited upon H-1 PV infection. Taken altogether, our
results confirm H-1 PV relevance in therapy by demonstrating ex
vivo its direct immunomodulating potential, possibly resulting in
improved antitumor immunity, without inducing Treg cell
activation.
Results
PHA-activated PBMCs are affected by H-1 PV infection
For all the experiments performed on human PBMCs, cells
were isolated from healthy donors’ blood, PHA-activated or not,
and inoculated with increasing amounts of purified H-1 PV (MOI
1, 5 and 25) or mock-treated from 24 h to 120 h. The impact of
such treatments was first analyzed by assessing the distribution of
PBMC main cell populations using flow cytometry (Table 1). After
24, 48 and 72 h of infection, cells were collected and labelled for
appropriate cell surface antigens. As reported in Table 1, H-1 PV
exerts no significant effect on the different cell populations when
they are not activated, except for Natural Killer (NK) cell fraction
whose frequency sustains a slight, viral dose-dependent decrease.
However, under PHA stimulation conditions, B cells, CD8 T cells
and NK cells rates seem to undergo a decrease that may be more
or less significant depending on the cell type. Meanwhile, CD4+ T
cells do not seem to be impaired by H-1 PV inoculation since their
frequency remains remarkably stable under any experimental
conditions.
To validate the impact of H-1 PV infection on freshly isolated
PBMCs, we have reproduced the 72 h p.i condition using PBMC
from 4 different donors (Table 2 and Fig. 1A). Results obtained
especially show that, within activated PBMCs, B lymphocyte rates
are clearly decreased upon infection whereas NK cells and the
CD8+ T lymphocytes are slightly decreased. However, concerning
the CD4+ T lymphocytes, one can observe that the level is
maintained throughout the infection.
Infected PBMCs were further analyzed with regard to their
proliferation ability and viability. On one hand, cell proliferation
was assessed using a test based on the metabolic incorporation of
tritiated thymidine into cellular DNA. We clearly observed that
PHA-activated PBMC proliferation ability is dramatically im-
paired in a viral dose-dependent manner (Fig. 1B). On the other
hand cell viability was measured using a test based on a
bioluminescent reaction measuring the amount of ATP present
in living cells. The results perfectly correlate with proliferation
assays since they show a major virus-dependent decrease in PHA-
activated PBMC viability upon H-1 PV infection, unlike non
activated cells whose viability is preserved (Fig. 1C). Cell
proliferation impairment is statistically significant 72 hours post-
infection at MOI 5 and 25 (p,0,05) when compared to Mock
condition and so is cell viability decrease whatever the MOI is
(p,0,05).
Table 1. Main cell populations fractions within non activated or PHA-activated human PBMCs at 24, 48 and 72 h after H-1 PV
infection.
Markers Status 0 h p.i 24 h p.i 48 h p.i 72 h p.i
Mock MOI 1 MOI 5 MOI 25 Mock MOI 1 MOI 5 MOI 25 Mock MOI 1 MOI 5 MOI 25
CD3CD4 NA 52,4 55,4 54 55 56,6 51,8 53,7 54,6 54,5 52,2 56 48,3 53,2
A 48,7 52,3 54,2 57,3 35,4 31,7 31,5 31,5 34,5 44,1 29,3 28,8
CD3CD8 NA 10,7 17,1 16,4 18 17,9 22,9 16,2 24,4 17,2 19,9 19,9 46,3 13
A 29,4 31,7 30,4 28,3 26,5 24,5 23,3 27,4 18,2 14,4 3,85 5,72
CD19CD20 NA 11,4 18,4 16,9 17,5 16,7 16,1 20,1 18,2 19,9 24,1 20 15,2 17,8
A 23,6 28,1 29,2 25,4 35,8 33,7 31,4 27,2 65,2 67,9 33,4 30
CD3CD56 NA 5,25 4,82 4,57 4,73 3,39 4,34 2,69 2,97 2,65 4,27 2,71 2,36 1,34
A 4,81 5 4,67 3,39 4 4,49 4,36 3,41 3,5 4,08 2,61 1,24
CD3CD30 NA 0,21 0 0 0,02 0,04 0,27 0 0,04 0,1 0,53 0,39 0,23 0,37
A 2,73 3,12 4,47 5,58 7 6,33 4,69 4,44 3,96 1,57 0,62 3,41
CD3CD69 NA 0 0,23 0,18 1,28 0,58 0,04 0,3 0,56 0,51 0,33 0,68 0,43 0,55
A 1,96 1,7 1,65 0,95 24,7 20,8 18 17,1 12,4 16,3 28,5 34,3
p.i: post-infection; NA: non activated PBMCs; A: activated PBMCs; MOI: multiplicity of infection.
Freshly isolated PBMCs were inoculated with increasing amounts of H-1 PV or mock-treated. For each condition, cells were labelled with appropriate antibodies and the
fraction of each cell population was analyzed using flow cytometry. Results are expressed as percentages of total cells within PBMCs. CD3+CD4+, CD3+CD8+,
CD19+CD20+ and CD3+CD56+ respectively indicate the % of CD4+ helper T cells, CD8+ effector T cells, B cells and NK cells within PBMCs. CD3+CD69+ and CD3+CD30+
respectively indicate the % of early and late activated T cells within PBMCs.
Representative data for all markers.
doi:10.1371/journal.pone.0032197.t001
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For each condition, pictures of the cells were taken in the course
of infection. An overall visual analysis showed that H-1 PV
inoculation causes important morphological changes to PHA-
activated PBMCs, leading to cell gathering in a viral dose-
dependent manner (Fig. 2A). Cell aspect made us think of
overactivation plates or cell death outward signs so we performed
a cytotoxicity assay to settle on either possibility. The test, which is
based on a bioluminescent reaction measuring the leak of a
cellular marker from cytoplasm to culture medium, allows the loss
of plasma membrane integrity to be revealed. 72 h after H-1 PV
inoculation, there was a 4- to 6-fold increase in stimulated PBMC
basal lysis whatever the dose of virus is (Fig. 2B). So H-1 PV seems
responsible for killing PHA-activated cells, but possibly in an
indirect way. At the same time, PBMC total protein extracts were
prepared in the course of infection and analyzed by Western
blotting. Non Structural protein 1 (NS1) plays a crucial role in H-1
PV life cycle achievement since it is involved in viral DNA
replication, viral proteins expression and also cytotoxicity,
allowing progeny virions to be released [13,14,15]. In this respect,
we consequently searched for NS1 (76 kDa) in infected PBMCs.
As shown in Figure 2C, PHA-activated PBMCs are able to
produce NS1 in a viral dose-dependent manner. We also noticed
that a slight amount of the protein becomes visible in non
activated PBMCs under MOI 5 and 25 conditions. Both caspase 3
and PARP cleavage is characteristic of immune cells activation at a
molecular level. It is also a well-known marker of ongoing
apoptosis. In the context of H-1 PV-infected PBMCs, caspase 3
and PARP are indeed cleaved under activation conditions but
their expression rate remains stable whatever infection conditions
are (Fig. 2C). This suggests that PHA-activated PBMCs die in a
caspase 3-independent manner upon H-1 PV infection. Besides,
considering that H-1 PV typically induces the lysis of productively
infected cells, we asked whether NS1 production was followed by
the release of newly generated virions. PBMCs and culture
supernatants were then collected and tested according to the
TCID50 method in order to quantify intracellular and released
virions. We were able to detect the presence of infectious viral
particles. However, the quantity did not exceed the inoculum that
was not removed from the cells, and even tended to decrease
(Fig. 2D). This shows that PBMCs do not support an H-1 PV
productive infection despite their ability to express NS1 protein.
PHA-activated PBMCs are overactivated during H-1 PV
infection and secrete Th1 and Th2 type cytokines
Cells were collected and CD3+ T cells were analyzed for the
expression of early (CD69) and late (CD30) activation markers
using flow cytometry. In a very interesting manner, T lymphocytes
(CD3+) keep their ability to get activated upon H-1 PV infection.
The virus even potentiates it, as evidenced by an increase in the
expression of respectively early and late activation markers CD69
and CD30. Results show that CD69 and CD30 expression is
increased at the surface of activated CD3+ T cells in a viral dose-
dependent way (Fig. 3A). Moreover, culture supernatants were
collected and tested for cytokine detection using Enzyme-Linked
ImmunoSorbent Assay (ELISA) in order to assess the time course
of PBMC cytokine release. We observed that H-1 PV enhances
PHA-activated PBMC ability to secrete Th1 cytokines such as IL-
2 and IFN-c (Fig. 3B) but also Th2 cytokines, namely IL-4 and IL-
10 (Fig. 3B). Interestingly, H-1 PV is also able to induce non
activated PBMC late IL-4 secretion (120 h after the inoculation).
Remarkably, these increased cytokine secretions depend on the
viral dose and some of them remain detectable up to 120 h after
H-1 PV inoculation.
Unlike PBMCs, CD4+ T cells do not undergo any major
impairment upon H-1 PV infection
For all the experiments performed on human CD4+ T cells,
PBMCs were first isolated from healthy donors’ blood. Then
CD4+ T cells were negatively selected, activated (or not) using
both anti-CD3 and anti-CD28 antibodies and inoculated with
increasing amounts of H-1 PV (MOI 1, 5 and 25) or mock-treated
from 24 h to 120 h. First, we analyzed infected CD4+ T cells in
terms of proliferation ability and viability as described above for
PBMCs. The results showed that CD4+ T cell proliferation ability
is not altered upon H-1 PV infection whether cells are activated or
not (Fig. 4A). In the same manner, H-1 PV does not affect CD4+
T cell viability (Fig. 4B). Slight differences between the subgroups
concerning both cell proliferation and viability were not
statistically significant (p.0,1). Moreover, pictures of the cells
were taken in the course of infection and showed that H-1 PV
inoculation is not related to any major morphological changes
(Fig. 4C). Besides, cytotoxicity assays did not prove any increase in
non activated and activated CD4+ T cell basal lysis (Fig. 4D).
Nevertheless, at a molecular level, Western blot analysis revealed
that CD4+ T cells transiently express a slight, dose-dependent
amount of NS1 protein.
H-1 PV preserves or even enhances non-activated and
activated CD4+ T cell secretion ability
In the course of infection, CD4+ T cells were collected and
analyzed for the expression of early CD69 and late CD30
activation markers using flow cytometry. Activated CD4+ T cell
expression of both markers is increased from the beginning of
infection (Fig. 5A). And interestingly, CD30 expression is also
enhanced in infected, non activated CD4+ T cells (Fig. 5A). At the
same time, culture supernatants were tested for cytokine detection
using ELISA method. CD4+ T cells keep their ability to secrete
Table 2. Main cell populations fractions within non activated
or PHA-activated human PBMCs at 72 h after H-1 PV infection.
Markers Status 0 h p.i 72 h p.i
Mock MOI 1 MOI 5 MOI 25
CD3CD4 NA 24,67 31 33,25 33,8 36,63
A 26,7 28,58 28 28,2
CD3CD8 NA 9,91 19,8 19,45 20,4 20,68
A 18,33 17,8 16,49 16,13
CD19CD20 NA 4,35 8,145 7,22 6,25 6,54
A 18,10 18,70 10,03 9,20
CD3CD56 NA 8,3 11,42 9,38 9,49 9,09
A 11,55 12,30 11,40 10,69
p.i: post-infection; NA: non activated PBMCs; A: activated PBMCs; MOI:
multiplicity of infection.
Freshly isolated PBMCs were inoculated with increasing amounts of H-1 PV or
mock-treated. For each condition, cells were labelled with appropriate
antibodies and the fraction of each cell population was analyzed using flow
cytometry. Results are expressed as percentages of total cells within PBMCs.
CD3+CD4+, CD3+CD8+, CD3-CD20+ and CD3-CD56+ respectively indicate the
% of CD4+ helper T cells, CD8+ effector T cells, B cells and NK cells within
PBMCs.
Mean data of 4 independent experiments from 4 different donors.
doi:10.1371/journal.pone.0032197.t002
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Very interestingly, H-1 PV is even able to enhance activated
CD4+ T cell ability to release IL-2 right from the beginning of the
infection, and IL-4 at early and late infection stages (24 h and
120 h after the inoculation) (Fig. 5B). Noticeably, H-1 PV also
induces IL-2 secretion in non activated CD4+ T cells from 24 to
72 h after the inoculation (Fig. 5B).
Unlike PBMCs, neutrophils cells do not undergo any
major impairment upon H-1 PV infection
Isolated neutrophils cells were LPS-activated or not (1 mg/ml),
and inoculated with increasing amounts of purified H-1 PV (MOI
1, 5 and 25) or mock-treated from 24 h to 72 h. The impact of
such treatments was first analyzed by pictures of the cells which
were taken in the course of infection. An overall visual analysis
showed that H-1 PV inoculation is not related to any major
morphological changes (Fig. 6A).
Then, we analyzed infected neutrophils in terms of viability as
described above for PBMCs and CD4+ T cells. Although we
observed a decrease in the viability of neutrophils 18 h after
infection, it is not related to an effect of H-1PV but to the fact
(and it is well documented) that isolated neutrophils can not be
kept very longer in culture. Thus, H-1 PV does not affect
neutrophil viability whatever the MOI and up to 72 hours of
contact (Fig. 6B).
Finally, we confirmed that infected neutrophils did not express
NS1 protein even transiently, confirming the complete absence of
H-1 PV effect on this immune sub-population (Fig. 6C).
Figure 1. PHA-activated PBMCs are affected by H-1 PV infection. PBMCs were inoculated with increasing amounts of purified H-1 PV or
mock-treated. MOI : multiplicity of infection, expressed as the number of plate-forming unit/cell; p.i : post-infection. A. CD8+ effector T cell, B
lymphocyte and NK cell populations are affected by H-1 PV infection within PHA-activated PBMCs, whereas CD4+ helper T cells are not. Cells were
collected 72 h p.i and labelled for appropriate cell surface antigens and the fraction of main lymphocyte populations within PBMCs was analyzed
using flow cytometry. Results are expressed as percentages of total cells within PBMCs. B. PHA-activated PBMC proliferation ability is decreased upon H-
1 PV infection. Cell proliferation was assessed by metabolic incorporation of tritiated thymidine into cellular DNA. Assays were performed at different
times after H-1 PV inoculation but only 48 and 72 h p.i conditions are shown. Results from one representative experiment are represented as means
of triplicate wells with 6 standard deviation bars and expressed in count per minute (cpm). Statistical analysis for 4 independent experiments was
performed using a Mann-Whitney test (* p,0,05; ** p,0,01 relative to Mock condition). C. PBMCs viability is decreased upon H-1 PV infection. Cell
viability was evaluated using a test based on a bioluminescent reaction measuring the amount of ATP present in living cells. Assays were performed
at different times after H-1 PV inoculation but only 48 and 72 h conditions are shown. Results from one representative experiment are represented as
means of trilplicate wells with 6 standard deviation bars and expressed in relative light unit (RLU). Statistical analysis for 4 independent experiments
was performed using a Mann-Whitney test (* p,0,05 relative to Mock condition). Representative data from 4 independent experiments.
doi:10.1371/journal.pone.0032197.g001
Effect of H-1 PV on Human Immune Cells
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while inhibiting their suppressive activity
CD4+CD25+ regulatory T cells (Treg) play an indispensable role
in maintaining immunological unresponsiveness to self antigens and
in suppressing excessive immune responses deleterious to the host.
Intheparticularcontextofcancer,Treg cellshave been increasingly
demonstrated to play an active and significant role in the pathology
progression and suppress antitumor-specific immunity. Thus,
assessing Treg cell status has become a crucial point in the area of
new clinical strategies development [11,12]. So, we investigated the
impact of H-1 PV on both regulatory T cell phenotype and
function. Treg cells were isolated from healthy donors PBMCs and
extemporaneously analyzed for their purity rate using flow
cytometry. For this purpose, we assessed the expression of Treg
cell-associated proteins, namely CD25 (IL-2 receptor a-chain),
CD127 (IL-7 receptor a-chain) and FoxP3 (a transcription factor)
[16]. CD4 and CD25 high expression defines cell purity which is
superior to 95%. CD4+CD252 cell fraction slightly expresses
CD25 or even does not at all (Fig. 6A). Lack of CD127 expression
has recently been described to be characteristic of functional Treg
cells. In contrast, CD4+CD252 cells do express this molecule. As
shown in Figure 7A, we confirmed that 90% of CD4+CD25+ cells
but only 14% of CD4+CD252 cells do not express CD127. In the
same way, the analysis of intracellular FoxP3 expression shows that
86% of freshly isolated Treg cells express this protein whereas only
12% of CD4+CD252 cell fraction do. As previously described for
PBMCs and CD4+ T cells, Treg cells were then infected with
increasing amounts of H-1 PV or mock-treated for 24 or 48 h. The
cells were first analyzed by flow cytometry to assess the impact of
such treatments on Treg cell phenotype. The results are reported in
Figure 7B and reveal no significant differences in the expression of
Treg cell-associated markers, whether the cells are activated or not.
Once again cell viability was evaluated using the same biolumines-
cent test which shows that H-1 PV inoculation does not affect
activated or non activated Treg cell survival (Fig. 7C).
Regulatory T cells are known to be anergic upon anti-CD3 and
anti-CD28 antibodies in vitro stimulation whereas PBMCs are able
to proliferate under these conditions. The functional suppressive
ability of freshly isolated Treg cells was assessed using a Mixed
Leukocyte Reaction (MLR) test between autologous PBMCs and
Figure 2. H-1 PV exerts its effect on PHA-activated PBMCs in an NS1-dependent manner. PBMCs were inoculated with increasing
amounts of purified H-1 PV or mock-treated. MOI : multiplicity of infection, expressed as the number of plate-forming unit/cell; p.i : post-infection. A.
H-1 PV alters PHA-activated PBMC morphology. For each condition, pictures of cells were taken in the course of infection but only those taken 48 h
post-infection are shown. Scale bar=100 mm. B. PHA-activated PBMCs are lysed upon H-1 PV infection. H-1 PV cytotoxicity was assessed using a test
based on a bioluminescent reaction measuring the leak of a cellular marker from cytoplasm to culture medium, which reveals the loss of plasma
membrane integrity. Assays were performed at different times after H-1 PV inoculation but only 48 and 72 h conditions are shown. Results are
represented as means of triplicate wells with 6 standard deviation bars and expressed in relative light unit (RLU). C. PHA-activated PBMC death upon
H-1 PV infection is related to NS1 protein expression but does not depend on caspase 3 activation. Non activated (NA) and activated (A) PBMC total
protein extracts were prepared in the course of infection. Equal amounts of proteins were separated by 4–12% SDS-PAGE and analyzed by Western
blot for the presence of NS1 protein, cleaved caspase 3 and both full-length and cleaved PARP. b-actin was used as a loading control. D. PBMCs do not
support an H-1 PV productive infection. Both PBMCs and culture supernatants were collected and tested for the presence of infectious viral particles
using the Tissue Culture Infectious Dose 50 method. The graph represents the time course of both released and non-released virions amounts which
were added and expressed in plaque forming unit (pfu). Representative data from 3 independent experiments.
doi:10.1371/journal.pone.0032197.g002
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determined after 48 h. Cell proliferation was measured using
metabolic incorporation of tritiated thymidine into cellular DNA.
Ex vivo human Treg cells still exert their suppressive activity in a
dose-dependent manner, inhibiting up to 80% of PBMC
proliferation (Fig. 7D). Regarding these results, we chose to
perform our experiments under the 4 PBMCs to 2 Treg cells ratio
(arrow, Fig. 7D) and investigated whether H-1 PV could affect
Treg function. The MLR test was slightly adjusted to respond to
our hypothesis since we performed it using autologous PBMCs and
Treg cells, with or without H-1 PV. Under basal conditions (i.e. no
stimulation and no virus) Treg cells are able to inhibit PBMC
proliferation up to 30%. When H-1 PV is added, an additional
impairment is expected according to the data depicted above. We
indeed noticed an additional decrease of PBMC proliferation,
especially under MOI 5 condition but very interestingly this
decrease is weaker than expected when cells are infected with a
higher amount of virus (MOI 25) (Fig. 7E). This strongly suggests
that H-1 PV may inhibit Treg cell-mediated suppressive activity.
Other possible alterations of Treg cell activity were also
evaluated. More particularly ELISA assays indicate that Treg cell
cytokine pattern (IL-2, IFN-c, TGFb and IL-10) remains
Figure 3. PHA-activated PBMCs are overactivated during H-1 PV infection and secrete Th1 and Th2 type cytokines. PBMCs were
inoculated with increasing amounts of purified H-1 PV or mock-treated. MOI : multiplicity of infection, expressed as the number of plate-forming unit/
cell. A. Early and late activation marker expression is increased at the surface of PHA-activated PBMCs upon H-1 PV infection. In the course of infection,
cells were collected, labelled for the expression of early (CD69) and late (CD30) activation markers and analyzed using flow cytometry. Results are
expressed as percentages of activated cells within T lymphocytes (CD3+ cells). B. H-1 PV enhances the ability of PHA-activated PBMCs to secrete Th1 and
Th2 type cytokines. In the course of infection, culture supernatants were collected and tested for cytokine detection by enzyme-linked
immunosorbent assay (ELISA). Results are expressed in pg/ml as means of duplicate wells and after subtraction of the background value. Statistical
analysis for 3 independent experiments was performed using a Mann-Whitney test (* p,0,05; ** p,0,01 relative to Mock condition). Representative
data from 3 independent experiments.
doi:10.1371/journal.pone.0032197.g003
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PV does not modify the anergic condition of Treg cells upon anti-
CD3 and anti-CD28 activation. Massive IL-2 amounts combined
with co-culture with irradiated autologous PBMCs are the only
treatment which allows Treg cells to proliferate. Under these
culture conditions we did not show any significant difference in
Treg cell proliferation ability either (data not shown).
H-1 PV is able to slow down and stabilize the growth of
nasopharyngeal carcinoma in humanized SCID mice
The results are presented in Tumor Volume Index versus days
post-treatment in Figure 8B. Although we have seen a progressive
increase in tumor size for the four groups of mice, only the groups,
which did not receive H-1 PV, saw their tumors grow to 6–7 times
the original size. In addition, it seems that reconstitution with a
simple immune system does not limit this growth (Fig. 8B).
In contrast, in two groups of mice that received H-1 PV, we see
indeed increased tumor size up to 20 days after treatment.
However, we showed that this growth does not exceed a maximum
of three times the size of the primary tumor, as previously
described in the work of Jean Rommelaere’s team [34]. In
addition and very interestingly, we observe that the size of these
tumors stabilized to stay below the maximum threshold of 3.
Furthermore, we found a small decrease in tumor size in the
group of mice reconstituted by human PBMC. This decrease in
the presence of PBMC was reproducible. Unfortunately, the large
variability in the initial tumor size did not allow us to validate
statistically this decrease. In addition, we observed no tumor
growth in all mice that had developed a very small tumor (difficult
to measure) and who received H-1 PV regardless of immune
reconstitution.
Discussion
Oncolytic viruses, such as H-1 parvovirus, are currently
considered serious candidates for cancer therapy because they
Figure 4. Unlike PBMCs, CD4+ T cells do not undergo any major impairment upon H-1 PV infection. CD4+ T cells were inoculated with
increasing amounts of H-1 PV or mock-treated. MOI : multiplicity of infection, expressed as the number of plate-forming unit/cell; p.i : post-infection.
A. CD4+ T cell proliferation ability is not altered upon H-1 PV infection. Cell proliferation was assessed by metabolic incorporation of tritiated thymidine
into cellular DNA. Only 48 and 72 h p.i conditions are shown. Results are represented as means of triplicate wells with 6 standard deviation bars and
expressed in count per minute (cpm). B. H-1 PV does not affect CD4+ T cell viability. Cell viability was evaluated using a test based on a bioluminescent
reaction measuring the amount of ATP present in living cells. Only 48 and 72 h p.i conditions are shown. Results are represented as means of
triplicate wells with 6 standard deviation bars and expressed in relative light unit (RLU). C. Infection of CD4 T cells by H-1 PV is not related to any
morphological changes. For each condition, pictures of cells were taken in the course of infection but only those taken 48 h after H-1 PV inoculation
are shown. Scale bar=100 mm. D. H-1 PV does not modify CD4+ T cell basal lysis. H-1 PV cytotoxicity was assessed using a test based on a
bioluminescent reaction measuring the leak of a cellular marker from cytoplasm to culture medium, which reveals the loss of plasma membrane
integrity. Results are represented as means of triplicate wells with 6 standard deviation bars and expressed in relative light unit (RLU). E. CD4+ T cells
transiently express a slight amount of NS1 protein. Equal amounts of total CD4+ T cell proteins were separated by 4–12% SDS-PAGE and analyzed by
Western blot for the presence of NS1 protein. Erk2 was used as a loading control. Representative data from 2 independent experiments.
doi:10.1371/journal.pone.0032197.g004
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potential of such anticancer agents could allow effective and less
aggressive treatments to be developed. However, whether H-1 PV
effects are also associated with the induction of specific immune
responses that could potentiate its oncosuppressive properties
remains to be defined. The present study shows for the first time
that H-1 PV is able to directly induce an effective immune
response, which could enhance antitumor immunity, in addition to
its direct inherent oncolytic effect.
H-1 PV exerts several significant effects on PBMCs, but mostly
when they are activated. Whether activated PBMCs are sensitive
to H-1 PV infection is a hard question to be answered, depending
on the criteria to meet in order to satisfy this little-defined notion.
Basically, our results emphasize three major points : i) H-1 PV
induces some viral dose-dependent events : NS1 protein
expression and a decrease in both activated PBMC viability and
proliferation ability, ii) the infection is associated with cytolysis in a
dose-independent manner, and iii) newly generated infectious
particles were not detected. H-1 PV life cycle initiation relies on
host cell ability to activate early P4 promoter which is known to
drive NS1 protein expression [17]. This ability has been described
to be mostly exerted by transformed cells as they exhibit a specific
Figure 5. H-1 PV preserves or even enhances non-activated and activated CD4+ T cell secretion ability. CD4+ T cells were inoculated
with increasing amounts of purified H-1 PV or mock-treated as described in Materials and Methods section. MOI : multiplicity of infection, expressed
as the number of plate-forming unit/cell; p.i : post-infection. A. Early and late activation marker expression is increased at the surface of CD4+ T cells
upon H-1 PV infection. In the course of infection, cells were collected, labelled for the expression of early (CD69) and late (CD30) activation markers
and analyzed using flow cytometry. Results are expressed as percentages of activated cells within CD4+ T cell population. B. H-1 PV enhances CD4+ T
cell ability to secrete Th1 and Th2 type cytokines. In the course of infection, culture supernatants were collected and tested for cytokine detection by
enzyme-linked immunosorbent assay (ELISA). Results are expressed in pg/ml as the mean of duplicate wells and after subtraction of the background
value. Statistical analysis for 2 independent experiments was performed using a Mann-Whitney test (* p,0,05 relative to Mock condition).
Representative data from 2 independent experiments.
doi:10.1371/journal.pone.0032197.g005
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life cycle [18]. Nonetheless, NS1 protein detection proves that
activated PBMCs allow viral life cycle to be initiated. Even though
proliferating PBMCs are normal cells, our result is consistent with
the fact that early steps of H-1 PV life cycle, notably P4 activation,
are strongly dependent on host cell ability to enter S phase [19].
Moreover, strong ectopic NS1 protein expression has recently
been reported to cause a significant decrease in normal human
fibroblast viability [20], showing that transformation is not a
compulsory requirement for NS1 to affect cells. This statement
leads us to suggest that NS1 protein is responsible for PBMC
viability impairment. The ability of infected, activated PBMC to
proliferate also suffers a major decrease. This drop could result
from NS1 protein ability to block cell cycle at G2 stage [14,21].
But this hypothesis cannot be validated for sure as we did not
assess cell cycle progression. NS1 properties also result in H-1 PV
cytotoxicity [14,22]. Even though PBMC lysis is clearly linked to
the virus, the dose-independence of this phenomenon makes NS1
protein unlikely to be responsible for it. We suggest that both
viability impairment and cytotoxicity should be uncoupled. In
activated PBMCs, NS1 protein exerts probably more cytostatic
than cytolytic properties while cell lysis would rather be an indirect
effect occurring under any H-1 PV infection conditions and
mediated by immune cells. In the context of cancer treatment,
cytolysis should not be considered insurmountable for H-1 PV to
be used since this effect is only partial. Moreover, H-1 PV-induced
impairments of human immune cells are observed in an ex vivo
context. But in a living organism, a pool of haematopoietic stem
cells continually renew them and would then also recover the cell
loss due to H-1 PV infection. Besides, we did not detect any newly
generated virions, which would allow the administration of the
agent to be controlled in therapy. Further investigation would be
necessary to determine which steps of H-1 PV life cycle activated
PBMCs are not able to sustain. Because activated PBMCs display
an appropriate environment for H-1 PV to exert some of its
properties, they can be considered sensitive to the virus but only
partly and in an abortive way since they do not achieve the whole
viral life cycle. Despite these impairments, activated, H-1 PV-
infected PBMCs get overactivated, as pointed out by the
overexpression of CD69 and CD30. They also mostly keep, or
even enhance, their cytokine secretion, mainly the Th1 pathway.
This strongly suggests that H-1 PV is able to induce an effective
immunological response without any other in-between stimulation.
In contrast to PBMCs, CD4+ T cells do not undergo any
significant changes upon infection and thereby, are clearly
resistant to H-1 PV despite slight NS1 synthesis. This suggests
that a threshold has to be reached for NS1 to exhibit its properties
and/or that NS1 required post translational modifications are not
Figure 6. H-1 PV does not affect neutrophils viability. Human neutrophils cells were inoculated with increasing amounts of purified H-1 PV or
mock-treated. MOI : multiplicity of infection, expressed as the number of plate-forming unit/cell; p.i : post-infection. C. Infection of Neutrophils by H-1
PV is not related to any morphological changes. For each condition, pictures of cells were taken in the course of infection but only those taken 48 h
after H-1 PV inoculation are shown. Scale bar=100 mm. B. H-1 PV does not affect Neutrophils viability. Cell viability was evaluated using a test based on
a bioluminescent reaction measuring the amount of ATP present in living cells. 6 h, 18 h, 24 h, 48 h and 72 h p.i conditions are shown. Results are
represented as means of triplicate wells with 6 standard deviation bars and expressed in relative light unit (RLU). Representative data from 5
independent experiments.
doi:10.1371/journal.pone.0032197.g006
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proliferation, CD4+ T cells remain or become activated and
cytokine secretion-competent upon H-1 PV infection. Currently,
CD4+ T cells are described as playing a key role in immune
responses [24]. More particularly, CD4+ T helper responses (Th1
and Th2) are increasingly proving to mostly support antitumor
immunity [25,26], which is what we reported upon H-1 PV
infection. Indeed, IL-2 secretion increases and IFN-c remains
detectable, thus demonstrating that Th1 pathway is induced. This
is of special significance because Th1 response is strongly involved
in antitumor immunity [27] and usually associated with the
activation of (i) the major effector cell subpopulation, namely
CD8+ T cells and (ii) the commitment of CD4+T cell into
cytotoxic T cells[24,28]. Even though CD8+ T cells seem to be
targeted by H-1 PV within PBMCs, they are not totally cleared
upon infection. We suggest that CD8+ T cell cytotoxic properties
may be responsible for the cytolysis we reported on infected
PBMCs. On the other hand, naive CD4+ T cells were very
recently shown to be able to differentiate into Th1 cytotoxic T cells
that display the remarkable ability to eradicate on their own an
established human melanoma [29]. Thus, early IL-2 induction
reported here might have induced IFN-c release, and then CD4+
T cells to commit into effector T cells. This highlights another
crucial aspect of CD4+ T cells in tumor clearance and their
preserved functionality upon infection strengthens H-1 PV value
as a promising candidate in anticancer therapy [27]. Besides its
role in Th1 pathway and therefore antitumor immunity, IL-2
could also be used as a quantifiable biomarker of T cell activation.
Such a sustained secretion of IL-2 could allow H-1 PV vaccination
effect to be easily monitored using ELISA or ELISPOT assays
[30]. Even though Th1 pathway is clearly the one to be focused on
to target antitumor immunity, Th2 response is far from being
insignificant and has been pointed out in anticancer therapy since
specific antibodies can efficiently clear cancer cells [26,31,32].
Very interestingly, this pathway also seems to be initiated upon H-
1 PV infection, as suggested by IL-4 release.
And very recently, in parallel with our in vitro study on human
immune cells, Grekova S et al [33] aimed to establish whether
immunomodulating mechanisms participate in the recently
reported therapeutic potential of parvoviruses against pancreatic
carcinoma in a rat model. In this work, they extended their study
to pancreatic cancer and could show that this immunity can be
further transferred to naı ¨ve tumor-bearing recipients. Recently
they found that treatment of rat pancreatic tumors with H-1 PV
resulted in the appearance of viral transcript in the PDAC
(Pancreatic ductal adenocarcinoma)-draining celiac lymp nodes,
with expression lasting up to 10 days post virus inoculation [34].
This involvement of lymphoid tissues in parvoviral oncosuppres-
sion is further sustained by their last study which showed that
intratumoral treatment of PADC with H-1 PV led to the
enrichment of these tissues with T-cells, with bias toward a Th1
response as evidence by the marked induction of IFN-c expression.
Moreover, they observed a splenomegaly which seems to be in
part related to a general lymphocyte proliferation reaction, in
response to viral infection. All these results recently obtained, in a
rat model of pancreatic cancer [33] are in agreement with our
results. Dissecting in more details the relation between H-1PV and
the human immune system led to the consistent finding that H-1
PV can cause an increase in the CD4/CD8 ration both in rats and
humans and induce Th1 expression in both species. In addition,
all the experiences we have made on neutrophils show that H1-PV
has no deleterious effect on viability, proving that we can
definitively exclude a negative effect of PVH-1 on neutrophils.
Immune cell infection by H-1 PV leads to the induction of
events which are characteristic of a broad, complementary and
effective antitumor response. However, such a response is likely to
be countered by the concomitant involvement of immunoregula-
tory components. To investigate this aspect, we focused our
attention on CD4+CD25+ regulatory T cells, which turn out to be
the main mediators of active immune escape in cancer. In this
context, Treg cells have been shown to play a major role in
pathology progression as they are able to suppress antitumor
immune response [11]. Thus, assessing Treg cells status has
become a crucial point in the area of new clinical strategies
development. Treg cell phenotype was not altered upon H-1 PV
infection and neither was their proliferation nor viability, whether
they are activated or not. Treg cells are known to be major
producers of IL-10 which is notably the lead immunosuppressive
cytokine [35]. Besides, experiments performed on activated
PBMCs showed a significant dose-dependent increase in IL-10
release upon infection (Fig. 3). Yet, it cannot be attributed to Treg
cells as H-1 PV does not modify their cytokine secretion pattern
(data not shown). However, IL-10 is also involved in humoral
immune response enhancement together with other cytokines in
vivo and monocytes/macrophages are likely to secrete high
amounts of IL-10 when they are stimulated [36]. Even though
we did not study H-1 PV direct interplay with these cells, this
hypothesis is consistent with the fact that Th1 type cytokines are
induced upon infection, possibly leading to monocyte/macro-
phage activation. Moreover, Treg cell inoculation with high
amounts of virus seems to impair Treg cell ability to suppress
PBMC proliferation. Then, it is tempting to assume that in an in
vivo context, H-1 PV would not only be able to induce an effective
immune response but also prevent the immunosuppressive tumor
microenvironment from getting worse.
Concerning the results obtained in our in vivo model, they allow
us to conclude that H-1 PV is able to slow down and stabilize the
growth of nasopharyngeal carcinoma when injected in large
Figure 7. H-1 PV affects neither Treg cell phenotype nor viability while inhibiting their suppressive activity. Treg cells were inoculated
with increasing amounts of purified H-1 PV or mock-treated. MOI : multiplicity of infection, expressed as the number of plate-forming unit/cell; p.i :
post-infection. A. Control of Treg cell purity. Cells were labelled for Treg cell markers and analyzed using flow cytometry. Results are expressed as
percentages of CD4+CD25+, CD4+CD25+CD127- and CD4+CD25+FoxP3+ cells within the whole cell population. B. Treg cells do not undergo any
major phenotypical changes upon infection. Cells were labelled for Treg cell markers and analyzed using flow cytometry 48 h p.i. Results are expressed
as percentages of CD4+CD25+ and CD4+CD25+CD127- cells within the whole cell population. C. H-1 PV does not affect Treg cell viability. Cell viability
was assessed 24 and 48 h p.i using a bioluminescent test measuring ATP amount in living cells. Results are represented as means of triplicate wells
with 6 standard deviation bars and expressed in relative light unit (RLU). D. Ex vivo Treg cells are able to suppress autologous activated PBMCs
proliferation. Autologous PBMCs were activated (anti-CD3 and -CD28 antibodies) and cultured with increasing quantities of Treg cells. PBMCs
proliferation was assessed by metabolic incorporation of tritiated thymidine into cellular DNA 48 h p.i. Results are represented as means of triplicate
wells with 6 standard deviation bars and expressed in count per minute (cpm). The black arrow indicates the ratio chosen for further experiments. E.
H-1 PV is able to inhibit Treg cell suppressive activity. Autologous PBMCs were activated (anti-CD3 and -CD28 antibodies), cultured with Treg cells (4
PBMCs for 2 Treg cells) and mock- or H-1PV-treated. PBMC proliferation was assessed by metabolic incorporation of tritiated thymidine into cellular
DNA 48 h p.i. Results are represented as means of triplicate wells with 6 standard deviation bars and expressed in count per minute (cpm).
Representative data from 3 independent experiments.
doi:10.1371/journal.pone.0032197.g007
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3 to 210 mm
3). While it completely prevents tumor
growth when injected in the early stages of tumor development
(tumor not measurable).
Regarding the addition of an immune system in this model, it
appears that the PBMC are able to improve slightly decreased
tumor growth. However, this small but reproducible non-
significant decrease is not sufficient to conclude that the activation
of CD4+ T induced by H-1 PV promotes the onco-suppressor
effect of this oncolytic virus. In contrast, activation of CD4+ T can
have an important complementary role in the anti-tumor
response. Indeed, it is well known that activated CD4+ T can
promote dialogue between immune cells of the innate or adaptive
immunity, including the expansion of memory clones, lytic
mechanisms or induction of apoptotic mechanisms.
In conclusion, our results show for the first time that H-1
parvovirus displays a cytostatic and cytolytic effect on some
immune cells subsets, mostly upon activation conditions, while
preserving and directly activating crucial CD4+ T cells after a
single inoculation. Our approach is also particularly original since
no study in the field of parvovirotherapy has been focused on the
key aspect of immunosuppression for which we did not evidence
any sign of activation upon H-1 PV infection. Therefore, our study
proposes an optimal way of testing and proving H-1 PV
remarkable immunomodulating properties. With this regard, H-
Figure 8. H-1 PV is able to slow down and stabilize the growth of nasopharyngeal carcinoma in humanized SCID mice.
Immunodeficient SCID mice (Severe combined Immunodeficiency) were subcutaneously xenotransplanted with tumors of nasopharyngeal carcinoma
(NPC) induced by C15 cells (human primary tumor cells of NPC). A. Timeline which summarizes the experimental protocol followed. After
development of visible tumors, SCID mice were splenectomized and reconstituted (i.p) or not with 50.10
6 human PBMC. At the same moment they
also received or not H-1PV directly injected within the tumor. SCID mice received only one injection of H-1 PV throughout the protocol. B. Results are
presented in Tumor Volume Index versus days post-treatment. There is a progressive increase in tumor size for the four groups of mice. Only the
groups, which did not receive H-1 PV, saw their tumors grow to 6–7 times the original size. H-1 PV stabilize the growth of nasopharyngeal
carcinoma in humanized SCID mice. In two groups of mice that received H-1 PV, the growth of the tumor does not exceed a maximum of three
times the size of the primary tumor. The size of these tumors stabilized to stay below the maximum threshold of 3. Representative data from 2
independent experiments.
doi:10.1371/journal.pone.0032197.g008
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Materials and Methods
Cells
Blood cells were isolated from 17 healthy donors. Each donor is
associated to one particular cell population, except for 3 of them
whose PBMCs as well as CD4+ T cells were isolated.
PBMC isolation. Peripheral Blood Mononuclear Cells
(PBMCs) from healthy donors were isolated by standard density
gradient centrifugation using Ficoll-Paque PLUS (Amersham
Biosciences, Uppsala, Sweden). Donor blood was provided by
the Etablissement Franc ¸ais du Sang – Nord de France (EFS), in
accordance with the official ethics agreement between the latter
and the Centre National de la Recherche Scientifique (CNRS) –
De ´le ´gation Nord Pas-de-Calais et Picardie. The study was
approved by the Institut de Biologie de Lille (CNRS) and EFS
Institutional Review Boards, and informed consent was obtained
in writing for each donor. When appropriate, CD4+ T cell and
CD4+CD25+ cell isolation was further performed.
CD4+ T cell isolation. CD4+ T cells were isolated from
PBMCs using a negative selection protocol according to
manufacturer’s instructions (Miltenyi Biotec, Berlin, Germany).
Briefly, PBMCs are incubated for 10 minutes with a cocktail of
biotinylated antibodies directed against CD8, CD14, CD16,
CD19, CD36, CD56, CD123, TCRc/d and glycophorin A.
Anti-biotin magnetic beads are then added for 15 minutes.
Undesired cells are magnetically retained in a Magnetic-
Activated Cell-Sorting (MACSH) column placed in a MACSH
separator. The target cells pass through the column and are
collected as the enriched, unlabeled, cell fraction, depleted of non-
target cells. Flow cytometric analysis shows that more than 98% of
the isolated cells are CD4+ cells.
Regulatory T cell isolation. Human regulatory T cells
(Treg) isolationwasperformedusing the CD4+CD25+ regulatoryT
cell Isolation kit (Miltenyi Biotec), according to manufacturer’s
instructions. Briefly, PBMCs and then CD4+ T cells are isolated as
described above. Target cells, namely CD4+CD25+ cells, are then
labelled with anti-CD25 beads.Cellsaremagneticallyseparatedina
MACSH column placed in a MACSH separator. The flow-through
fraction can be collected as negative fraction depleted of the labeled
cells.Thelatter step isrepeated oncetoenhancethe yield and purity
of the expected cell fraction. Flow cytometric analysis shows that
more than 95% of the isolated cells are CD4+C25+ cells.
Neutrophils isolation. For all the experiments performed,
human neutrophils were isolated from healthy donors’ blood.
Whole blood is first centrifuged to remove platelet-rich serum. The
fraction containing the red blood cells, neutrophils and eosinophils
were isolated by standard density gradient centrifugation using
Ficoll-Paque PLUS (Amersham Biosciences, Uppsala, Sweden).
From that point, immediately place the aliquots on ice. Then, the
fraction is subjected to a lysis buffer (NH4CL 155 mM, KHCO3
10 mM, EDTA 0.1 mM) to remove red blood cells using a
standard protocol. After 15 min on ice, cells were again
centrifuged and the pellet was washed 3 times with PBS. Quality
control is performed by cell counting after classical staining (Eosin;
Methylene blue). And finally, the percentage of neutrophils was
evaluated by light microscopy. Only preparations containing more
than 95% of neutrophils were used. For subsequent analysis,
isolated neutrophils cells were LPS-activated or not (1 mg/ml)
(Sigma-Aldrich, St Louis, MO, USA) and inoculated with
increasing amounts of purified H-1 PV (MOI 1, 5 and 25) or
mock-treated from 24 h to 72 h.
Cell culture conditions. RPMI 1640 medium (Invitrogen,
Paisley, UK) supplemented with 10% human AB serum (BioWest,
Nuaille ´, France), 2 mM L-Glutamine, 1 mM sodium pyruvate,
10 mM non essential amino acids, 10 mM HEPES, 50 U/mL
streptomycin, 50 mg/mL gentamycin and 50 mM b-
mercaptoethanol was used as standard culture medium. Cells
were incubated at 37uC under controlled atmosphere (5% CO2
and 95% humidity) in a Hera Cell 150 incubator (Thermo
Electron, Cergy Pontoise, France). When appropriate, PBMCs
were activated using PHA (5 mg/mL). For CD4+ T cells
activation, anti-CD3 (1,5 mg/mL) (Clinisciences, Montrouge,
France) antibody was plate-bound by a 2 hours incubation at
37uC before the cultivation and soluble anti-CD28 antibody
(100 ng/mL) (Clinisciences) was added extemporaneously.
Flow cytometry
Cell immunophenotype was analyzed using EPICSH XL-MCL
cytometer (Beckman Coulter, Fullerton, CA, USA) powered by
EXPO 32 software. Cells were harvested, washed with phosphate-
buffer saline (PBS) (Invitrogen) and labelled with appropriate
fluorochrome-conjugated monoclonal antibodies (mAbs). Isotypic
control mAbs were systematically used for markers setting. Data
were analyzed and represented using Windows Multiple Docu-
ment Interface for Flow Cytometry Software (WinMDI) (Scripps
Research Institute, La Jolla, CA, USA).
Monoclonal antibodies (mAbs) directed against the relevant cell
surface antigens were used to characterize main cells populations
(PBMCs), cell activation status (PBMCs and CD4+ T cells) or cell
phenotype (Treg cells). Anti-CD3-phycoerythrin(PE)-cyanin(Cy)5-
mAb (BD Pharmingen, San Diego, CA, USA) was used to
discriminate T cells from non T cells. Within T cells, anti-CD8-
PE-mAb (Immunotech, Marseille, France) and anti-CD4-fluores-
cein isothiocyanate (FITC) or -PE-mAb (Immunotech) were
respectively used to discriminate CD8 from CD4 populations.
Within non T cells, anti-CD56-PE-mAb (BD Pharmingen) and
anti-CD19-PE-mAb (BD Pharmingen) were respectively used to
discriminate NK cells from B lymphocytes. Anti-CD4-PC5-mAb
(BD Pharmingen), anti-CD25-PE-mAb (Miltenyi Biotec) and anti-
CD127-FITC-mAb (Clinisciences) were used to characterize Treg
cells phenotype. Finally, anti-CD30-PE-mAb (Immunotech) and
anti-CD69-FITC-mAb (BD Pharmingen) were respectively used as
late and early activation markers.
Virus production and quantification, and cell infections
Briefly, NB-324K cells were transfected according to manufac-
turer’s instructions using ExGen 500 transfection reagent (Euro-
medex, Souffelweyersheim, France) with a plasmid containing
wild-type H-1 PV genome (pSR19, kindly provided by Pr. Jean
Rommelaere, Heidelberg, Germany) [37] and allowing infectious
viral particles to be generated. Cells were harvested 6 days after
transfection by scraping, pelleted and lysed in 50 mM Tris-HCl/
0,5 mM EDTA (pH 8,7) by two ‘‘freezing and thawing’’ cycles.
Cell debris were removed by centrifugation and supernatant was
collected for virus quantification (see below). MOLT 4 cells
(ATCC CRL-1582
TM) were then infected with NB-324K-
generated H-1 PV (Multiplicity of Infection or MOI=0,01;
expressed as the number of plate-forming unit/cell) for 3 days in
order to produce large amounts of virus. Newly generated virions
were collected as mentioned above and purified by iodixanol
gradient centrifugation as previously described [38]. H-1 PV stock
was quantified using Tissue Culture Infectious Dose 50 (TCID50)
method. Briefly, NB-324K cells were seeded in 96-well plates and
infected with serial dilutions of virus at the rate of 10 wells per
dilution. Cells were incubated at 37uC (95% humidity, 5% CO2)
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St Louis, MO, USA). Virus titers were calculated according to
Reed and Muench method (1938). Part of the stock was UV-
treated to inactivate virions and be used as a control. Cells
(PBMCs, CD4+ T cells or Treg cells) were infected at various
multiplicities of infection (MOI 1, 5 and 25). After cells cultivation
(10
6 cells/mL, whatever the cell culture tool is) and, if necessary,
activation, virus was added at the rate of 10% of culture medium
volume to allow proper spread and favor contact between cells and
virus. A part of cells was also treated with PBS-MK, iodixanol or
irradiated H-1 PV as controls. The inocula were not removed
from cells. Iodixanol condition is further mentioned as ‘‘Mock’’.
Cell proliferation assay
Cells were incubated with [methyl-
3H]-thymidine for the last
18 hours of culture and harvested on glass fibre filter (Printed
Filtermat A, Wallac, Turku, Finland) using Tomtec harvester
(Wallac). The filter was then sealed in a sample bag after drying
and addition of scintillation liquid (Beckman Coulter). Radioactive
thymidine, incorporated into replicated cellular DNA by prolifer-
ative cells, was detected by scintillation counting using a 1450
Trilux b-counter (Wallac) and measured in count per minute
(cpm). Results are expressed as means of triplicate wells.
Cell viability and cytotoxicity assays
In the course of infection, both cell viability and lysis were
assessed using respectively CellTiter-Glo Luminescent Cell
Viability assay and CytoTox-Glo Cytotoxicity assay according to
manufacturer’s instructions (Promega, Madison, WI, USA). The
former measures the amount of ATP present in living cells and the
latter evaluates the leak of a cellular marker from lysed cells
cytoplasm to culture medium. Data were achieved using Centro
LB 960 plate luminometer (Berthold, Thoiry, France) powered by
MikroWin 2000 Software. Results are expressed in relative light
unit (RLU) as means of triplicate wells.
Cytokine detection
Culture supernatants were tested for cytokine detection by
Enzyme-Linked ImmunoSorbent Assay (ELISA) method as
previously described [39]. For each cytokine, the culture
supernatant from about 10
5 cells was used. In this study, IL-2,
IL-4, IFN-c and IL-10 release was investigated using sandwich
ELISA based on colorimetric quantification. Antibodies pairs and
standards were purchased at BD-Pharmingen. A492 nm was
measured using a multichannel spectrophotometer (Multiskan
EX powered by Ascent Software, Thermo Electron). Results were
expressed as means of duplicate wells.
Western blotting
In the course of infection, cells were scraped directly in culture
medium and washed with PBS. Cell pellets were then lysed
(10 minutes on ice) in PY buffer consisting of 20 mM Tris-HCl,
50 mM NaCl, 5 mM EDTA, 1% Triton X-100, 0,02% sodium
azide and a cocktail of proteases inhibitors (Roche, Basel,
Switzerland). Cell debris were removed (20000 g, 15 minutes,
4uC), supernatants were collected and protein concentrations were
measured using Bio-Rad Protein Assay (Bio-Rad, Marnes la
Coquette, France) according to manufacturer’s instructions. Total
cell extracts (20 mg) were then analyzed by Western blotting. First,
proteins were separated by SDS-PAGE electrophoresis using
gradient pre-casts gels (4–12% gradient, Bis-Tris) (Invitrogen) and
then transferred onto PVDF membrane (Millipore, Molsheim,
France). The latter was blocked for 1 hour at room temperature in
blocking buffer containing 0,2% Aurora
TM blocking reagent (MP
Biomedicals, Illkirch Graffenstaden, France), 0,1% Tween20
(Sigma-Aldrich) and PBS (16), and incubated overnight at 4uC
with primary antibodies directed against : NS1 protein (SP8 rabbit
serum, 1:5000) (Faisst et al., 1995), cleaved caspase 3 (1:1000)
(D175, 5AE1, Cell Signaling, Danvers, MA, USA), PARP (1:1000)
(H-250, Santa Cruz Biotechnology, Santa Cruz, CA, USA), b-
actin (1:5000) (sc-47778, Santa Cruz Biotechnology) and Erk2
(1:1000) (sc-154, Santa Cruz Biotechnology). Membranes were
washed with blocking buffer, incubated for 1 hour at room
temperature with peroxydase-conjugated secondary antibodies
(anti-mouse and anti-rabbit, 1:10000) (GE Healthcare, Wauwa-
tosa, WI, USA) and washed again with blocking buffer. Specific
protein signals were visualized using Western LightningH Plus-
ECL, Enhanced Chemiluminescence Substrate kit (PerkinElmer,
Boston, MA, USA).
Regulatory T cell functionality assay
Mixed Leukocyte Reaction (MLR) assays were performed to test
Treg cell ability to either proliferate under activation conditions or
inhibit autologous PBMCs proliferative response. Autologous
PBMCs, Treg cells or both cell types were cultured in round-
bottom 96-well plates for 48 h. When appropriate, anti-CD3
(1,5 mg/mL) antibody was plate-bound by a 2 hour-incubation at
37uC before the cultivation and soluble anti-CD28 antibody
(100 ng/mL) (Clinisciences) was added extemporaneously and/or
cells were inoculated with H-1 PV as mentioned above. Cell
proliferation was then assessed as described above. Results are
expressed as means of triplicate wells.
SCID Mice model
Animals. Homozygous CB-17 scid/scid (SCID) mice derived
from breeding stocks provided by Dr M. Liberman (Standford
University, Standford, CA), with the permission of Dr M. Bosma
(Fow Chase Cancer Center, Philadelphia, PA), were bred and
maintained in microisolator cages and used between 4 and 8 wk of
age. The mice were kept under pathogen-free conditions without
prophylactic administration of antibiotic.
Tumor xenotransplantation. Briefly, anesthetized mice
were prepared for xenotransplantation by shaving the hair from
a 2-cm2 area. Mice were subcutaneously xenotransplanted with
nasopharyngeal carcinoma (NPC) tumors induced by C15 cells
(Human primary tumor cells of NPC). The protocol was approved
by the local Ethical Committee of the ‘‘Institut Pasteur de Lille’’.
Human PBMC reconstitution. We waited for the
development of visible tumors (about 6 to 8 weeks) before mice
were splenectomized and reconstituted or not with human PBMC
on day 0 (intraperitoneal injection of 50.10
6 PBMC isolated from
blood of healthy donor).
H-1 PV challenge. On day D0, the mice also received or not
H-1 PV which is directly injected within the tumor (approximately
10 injection points for a final estimated concentration of MOI 0.1).
Throughout the protocol mice received only one injection of H-1
PV.
Regular measurements of the tumor were performed from the
immune reconstitution and H-1 PV challenge (at D3, D7, D9,
D11, D15, D20, D22 and D23). During this period, some mice
had to be sacrificed for ethical reasons. Finally, all mice were
sacrificed at D23.
Under this experimental protocol, we made four separate
groups of mice: (i) A control group of C15 xenotransplanted SCID
mice which received neither PBMCs nor H-1 PV (n=5); (ii) A
group of xenotransplanted SCID mice receiving only PBMC
(n=5); (iii) A group of xenotransplanted SCID mice receiving only
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receiving both PBMC and H-1 PV (n=5).
Statistical analysis
The relevance of the results was validated using the statistical
rank sum Mann-Whitney test with Sigma-stat software.
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